Genmab A/S
GMAB
$31.94
$0.601.91%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 06/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 24.86% | 25.31% | 3.03% | 18.74% | 18.74% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 24.86% | 25.31% | 3.03% | 18.74% | 18.74% |
| Cost of Revenue | 47.37% | 54.76% | 52.71% | 103.57% | 103.57% |
| Gross Profit | 23.39% | 23.48% | 0.33% | 15.58% | 15.58% |
| SG&A Expenses | 42.36% | 31.75% | 5.99% | 11.63% | 11.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 32.39% | 27.32% | 19.87% | 9.07% | 9.07% |
| Operating Income | 13.06% | 19.68% | -29.97% | 37.93% | 37.93% |
| Income Before Tax | -30.26% | -69.67% | -90.07% | 37.79% | 37.79% |
| Income Tax Expenses | -109.20% | -57.14% | 200.09% | -16.35% | -16.35% |
| Earnings from Continuing Operations | -9.82% | -72.82% | -94.64% | 65.52% | 65.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.82% | -72.82% | -94.64% | 65.52% | 65.52% |
| EBIT | 13.06% | 19.68% | -29.97% | 37.93% | 37.93% |
| EBITDA | 12.50% | 19.61% | -28.33% | 35.79% | 38.75% |
| EPS Basic | -9.19% | -72.55% | -94.47% | 72.70% | 72.70% |
| Normalized Basic EPS | -13.80% | -47.05% | -46.73% | 31.98% | 31.98% |
| EPS Diluted | -9.41% | -72.79% | -94.44% | 73.16% | 73.16% |
| Normalized Diluted EPS | -14.01% | -47.51% | -47.43% | 32.33% | 32.33% |
| Average Basic Shares Outstanding | -0.69% | -0.99% | -3.06% | -4.16% | -4.16% |
| Average Diluted Shares Outstanding | -0.45% | -0.12% | -1.76% | -4.42% | -4.42% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |